Dermisonics, Inc.’ Test With Type-2 Diabetics Proves Ultrasound Component Of The U-Strip System Does Not Damage The Skin

IRVINE, CA -- (MARKET WIRE) -- September 19, 2006 -- Dermisonics, Inc. (OTCBB: DMSI) (FWB: FQC), a developer of painless injection-free ultrasonic transdermal drug-delivery patches and technologies with broad pharmaceutical and consumer applications, announced today that it successfully completed its HPT-4 human pilot trial of its proprietary U-Strip transdermal drug-delivery system in patients with Type-2 diabetes.